Thankfully for its shareholders, the Creso Pharma Ltd (ASX: CPH) share price is heading in the right direction at long last.
At the time of writing the pot stock is up 4.5% to 50.2 cents, reducing its 30-day decline to around 34%.
Why has it jumped?
Investors have been snapping up shares today after the company announced that it has signed a strategic agreement with leading Australian medicinal cannabis producer LeafCann.
According to the release, LeafCann will supply Good Manufacturing Practice-standard cannabis and hemp-derived materials to the company. These will then be used to produce therapeutic products for both the human and animal health markets.
Management believes this partnership advances Creso's leadership position in the growing Australian medicinal cannabis industry, placing it well to capitalise on the growth in the market following recent federal and state legislative changes.
Should you invest?
Creso Pharma is focused on developing products for the treatment of anxiety, epilepsy, chronic pain, osteoarthritis, and osteoporosis.
These are lucrative markets and could provide strong sales for the company if it is successful. But it is worth remembering that it is early days and there's a lot of work that will need to be done until these products are prescribed by doctors.
Like rivals Auscann Group Holdings Ltd (ASX: AC8) and Cann Group Ltd (ASX: CAN), Creso Pharma could have a bright future ahead of it. But for now it is just a little too early to make an investment in my opinion.
